Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cyclezyme ABXSAT:CYCLE -2.05%8 Current Ratio is 2.45 as of Mar. 2026, which is 38% below its 10-year median of 3.98. GuruFocus rates XSAT:CYCLE with a GF Score™ of 8/100. The stock has 3 warning signs investors should review. Among 1,605 Chemicals companies, Cyclezyme AB ranks better than 64.24% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Cyclezyme AB's current ratio for the quarter that ended in Mar. 2026 was 2.45.
Cyclezyme AB has a current ratio of 2.45. It generally indicates good short-term financial strength.
The historical rank and industry rank for Cyclezyme AB's Current Ratio or its related term are showing as below:
XSAT:CYCLE'
s Current Ratio Range Over the Past 10 Years
Min: 2.19 Med: 3.98 Max: 10.1
Current: 2.45
During the past 6 years, Cyclezyme AB's highest Current Ratio was 10.10. The lowest was 2.19. And the median was 3.98.
XSAT:CYCLE's Current Ratio is ranked better than 64.24% of 1605
companies
in the Chemicals industry
Industry Median: 1.89
vs XSAT:CYCLE: 2.45
Cyclezyme AB (XSAT:CYCLE) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Cyclezyme AB Current Ratio Related Terms
Cyclezyme AB Current Ratio Historical Data
* Premium members only.
The historical data trend for Cyclezyme AB's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSAT:CYCLE vs LIN, SHW, ECL: Current Ratio Comparison
For the Specialty Chemicals subindustry, Cyclezyme AB's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cyclezyme AB Current Ratio vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, Cyclezyme AB's Current Ratio distribution charts can be found below:
* The bar in red indicates where Cyclezyme AB's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cyclezyme AB (XSAT:CYCLE) has a Current Ratio of 2.45 as of Mar. 2026. This is 38% below median its historical median of 3.98. Over the past decade, Cyclezyme AB's Current Ratio has ranged from 2.19 to 10.10. According to the industry distribution chart, Cyclezyme AB ranks #574 out of 1605 companies in the Chemicals industry, placing it in the top 35.8%.
Is Cyclezyme AB's Current Ratio too high?
Cyclezyme AB's current Current Ratio of 2.45 is 38% below median its 10-year median of 3.98. Over the past 10 years, this metric has ranged from a low of 2.19 to a high of 10.10. The Chemicals industry median Current Ratio is 1.89. Cyclezyme AB's value of 2.45 is 29.6% above this industry median. Based on the distribution chart, Cyclezyme AB ranks #574 out of 1605 companies in the Chemicals industry, which is above the industry midpoint. Overall, Cyclezyme AB has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Cyclezyme AB's Current Ratio compare to LIN and SHW?
According to the Chemicals industry distribution chart, Cyclezyme AB ranks #574 out of 1605 companies for Current Ratio. This puts Cyclezyme AB in the upper half of its industry. The industry median Current Ratio is 1.89. Cyclezyme AB's value of 2.45 is 29.6% above this benchmark. Historically, Cyclezyme AB's own Current Ratio has ranged from 2.19 to 10.10 over the past decade. While the company's 10-year median is 3.98 vs. the industry median of 1.89, Cyclezyme AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Chemicals company?
The median Current Ratio among Chemicals companies is 1.89, based on 1,605 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cyclezyme AB's current Current Ratio of 2.45 is 29.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Chemicals industry, the median Current Ratio is 1.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cyclezyme AB's current Current Ratio is 2.45, which is 38% below median its own 10-year median of 3.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cyclezyme AB stock overvalued right now?
Cyclezyme AB (XSAT:CYCLE) has a current Current Ratio of 2.45. The current Current Ratio is 2.45, which is 38% below median its 10-year median of 3.98 and 29.6% above the Chemicals industry median of 1.89. Cyclezyme AB's overall GF Score™ is 8/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Cyclezyme AB (XSAT:CYCLE), the current Current Ratio is 2.45 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cyclezyme AB is a Sweden-based company that has developed an enzymatic platform focused on producing enzymes for green biochemical processes. This platform utilizes biotechnological methods to identify and improve enzymes capable of converting e.g. PET-based plastic materials for new building blocks. The company enables careful experiments and analyses of the behavior of different enzymes in the breakdown of e.g. PET material. The company refines its enzymes and also optimizes the processes for plastic recycling by combining experimental data with data analysis.
8GF Score
Get the complete analysis for XSAT:CYCLE
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSAT:CYCLE has been successfully added to your 
